



Esperion Therapeutics, Inc.  
Investor Relations Department  
3891 Rancho Drive  
Suite 150  
Ann Arbor, MI 48108  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: ESPR**

Last Trade:	32.83
Trade Time:	4:00 PM ET May 26, 2017
Change:	-0.45  (-1.352%)
Day Range	32.54 - 34.42
52-Week Range	9.40 - 48.21
Volume	397,013

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion Therapeutics is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly".

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 22, 2017 [Esperion Provides Update on Common Stock Trading Activity](#)
- May 19, 2017 [Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)
- May 18, 2017 [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- May 12, 2017 [Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference](#)
- May 4, 2017 [Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 22, 2017 [Annual Report \(10-K\)](#)
- Mar 6, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 4, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 3, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 4, 2016 [Quarterly Report \(10-Q\)](#)